Product Name: Serelaxin
CAS No: 99489-94-8
Purity: 95%
Molar Mass: 5963.04
Chemical Formula: C256H408N74O74S8
Synonyms: RLX030
Storage: Store at -20℃
Application:
Serelaxin (CAS: 99489-94-8) is a recombinant form of human relaxin-2, a hormone naturally produced during pregnancy. It functions as a vasodilator and has been investigated for its potential therapeutic applications in various cardiovascular conditions, particularly heart failure. Serelaxin acts by promoting vasodilation, reducing inflammation, and exerting anti-fibrotic effects, ultimately improving cardiac function and reducing symptoms associated with heart failure. Clinical trials have shown promising results, demonstrating serelaxin's ability to improve hemodynamic parameters, reduce hospitalizations, and improve mortality rates in patients with acute heart failure. Despite initial enthusiasm, further research is needed to fully elucidate serelaxin's mechanisms of action and optimize its clinical use in heart failure management.
Current Research:
Serelaxin is a recombinant form of the relaxin-2 hormone, which has garnered significant attention for its potential therapeutic benefits in treating cardiovascular and renal diseases, particularly acute heart failure (AHF). As a natural vasodilator, serelaxin is designed to relax blood vessels, reduce cardiac workload, and improve overall cardiovascular function. It represents a new approach in managing acute and chronic cardiovascular conditions, offering hope for better treatment outcomes compared to traditional therapies.
Mechanism of Action
Relaxin-2, the naturally occurring hormone in the body, plays a crucial role in pregnancy by helping to relax the uterine muscles, enhance blood flow, and promote tissue remodeling. It exerts its physiological effects primarily through binding to the relaxin receptor (RXFP1), which is present on a variety of tissues, including the endothelial cells lining blood vessels, cardiac tissues, and kidneys.
When administered as a therapeutic, serelaxin mimics the effects of endogenous relaxin-2. It works by promoting vascular relaxation, which helps to lower blood pressure and reduce the strain on the heart, making it an effective agent in managing conditions like acute heart failure, where reduced cardiac output and high blood pressure are common issues. Additionally, serelaxin has anti-fibrotic properties, which can help prevent or reverse the remodeling of tissues in the heart and kidneys that often accompanies chronic heart failure or renal insufficiency.
Serelaxin’s action on the renal vasculature also helps to increase renal blood flow and glomerular filtration rate (GFR), which can be beneficial in treating acute kidney injury (AKI) and acute decompensated heart failure. By improving fluid and electrolyte balance, serelaxin supports better kidney function and contributes to overall cardiovascular stability.
Current Research and Development
Serelaxin is primarily being studied in the context of acute heart failure and acute kidney injury. In clinical trials, such as the RELAX-AHF study, serelaxin demonstrated beneficial effects in patients with acute heart failure, including improvements in dyspnea (shortness of breath), reduction in heart failure symptoms, and better overall patient outcomes. The study showed that serelaxin significantly reduced the need for hospitalization and showed potential for improving the quality of life in heart failure patients.
In addition to heart failure, serelaxin is also being explored in acute kidney injury (AKI), which is common in patients with severe cardiovascular disease. Research suggests that serelaxin may offer a dual benefit by improving both renal function and cardiac performance, particularly in patients with heart failure complicated by renal dysfunction.
The potential of serelaxin extends beyond acute conditions. Ongoing studies are investigating its use in chronic heart failure, where its vasodilatory and anti-fibrotic effects may help manage the long-term progression of heart disease, potentially improving the prognosis for patients with advanced heart failure.
Advantages Over Current Therapies
One of the key advantages of serelaxin over traditional therapies for heart failure, such as diuretics or ACE inhibitors, is its unique mechanism of action that targets the underlying vascular dysfunction and fibrosis. While diuretics help reduce fluid overload and ACE inhibitors target blood pressure regulation, serelaxin directly addresses the underlying vascular and endothelial dysfunction, helping to relax blood vessels, reduce pressure, and prevent tissue damage due to chronic inflammation and fibrosis.
Another advantage is its potential to improve renal function in patients with both heart failure and acute kidney injury (AKI), a condition that significantly worsens outcomes in heart failure patients. Traditional treatments for heart failure often worsen kidney function or are not as effective in managing renal complications. Serelaxin’s dual action on both the heart and kidneys makes it a promising candidate for treating these complex, multi-organ conditions.
Safety and Tolerability
In clinical trials, serelaxin has been generally well tolerated, with a safety profile that is favorable compared to other cardiovascular agents. The most commonly reported adverse effects have been mild and include headache, nausea, and hypotension (low blood pressure). Serious adverse events have been rare, though monitoring of blood pressure is advised due to the drug’s vasodilatory effects.
Future Directions
As clinical trials progress, the potential of serelaxin to become a cornerstone therapy in acute heart failure management is increasingly recognized. Research is also ongoing to explore its role in chronic heart failure, acute kidney injury, and even in combination therapies with other agents, such as neprilysin inhibitors or sodium-glucose co-transporter-2 (SGLT2) inhibitors, which have also shown promise in heart failure management.
Additionally, ongoing efforts are focused on understanding the long-term benefits of serelaxin in patients with chronic kidney disease (CKD) and cardiorenal syndrome, where heart and kidney dysfunction are interrelated. As our understanding of serelaxin’s multi-system effects deepens, it may be positioned as a key player in the management of complex cardiovascular and renal conditions.
Conclusion
Serelaxin represents a promising therapeutic agent with the potential to significantly improve the treatment landscape for acute heart failure and acute kidney injury. By targeting the underlying vascular dysfunction and offering benefits to both the heart and kidneys, serelaxin offers a new approach in managing these complex conditions. As ongoing clinical trials continue to explore its full range of applications, serelaxin has the potential to become a valuable addition to the cardiovascular and renal therapeutic armamentarium.
Reference:
Get a Quote
LinkPeptide
